At Nura Bio (previously known as Proneurotech Inc.), we envision a world where the diagnosis of a neurological disorder comes with the hope of a cure. Expanding on recent breakthroughs in crucial neurodegenerative pathways, we are positioned to deliver transformative neuroprotective therapies to prevent and protect against neuronal loss and related neuroimmune dysregulation. Our research and development strategy is currently centered on two approaches: prevention of neuronal loss to preserve neurological function; and restoring the function of the neuron-glia axis to improve the nervous system’s immune surveillance capacity in response to neurological injury. Our discovery engine and emerging multi-target pipeline spans these approaches and is well positioned to address a broad range of neurological diseases. Nura Bio’s lead program is the SARM1 inhibitor program. SARM1, has recently emerged an axon-intrinsic metabolic sensor that is a pivotal driver of axonal degeneration and neuronal integrity. Axon degeneration is an early event in several neurological disorders, and halting it early has tremendous potential in the treatment of central, peripheral, and ocular neurological diseases.
Employees: 11-50
Total raised: $213M
Founded date: 2018
Investors 1
| Date | Name | Website |
| 28.07.2020 | The Column... | thecolumng... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 18.09.2024 | Series A | $140M | - |
| 31.07.2020 | Series A | $73M | - |
Mentions in press and media 7
| Date | Title | Description |
| 19.09.2024 | Nura Bio Secures $140 Million to Tackle Neurological Diseases | Nura Bio, a San Francisco-based biopharmaceutical company, has struck gold. It recently closed a whopping $140 million in Series A funding. This financial boost comes at a crucial time as the company gears up to advance its pipeline of neur... |
| 18.09.2024 | Nura Bio Raises More Than $140M in Series A Financing | Nura Bio, a San Francisco, CA-based clinical-stage, biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, raised more than $140M in Series A funding. This inc... |
| 18.09.2024 | Nura Bio: Neuroprotective Therapy Company Closes $68 Million (Series A) | Nura Bio, a clinical-stage biopharmaceutical company developing neuroprotective and small molecule therapies for treating debilitating neurological diseases, announced the closing of over $140 million in Series A funding. And this includes ... |
| 31.07.2020 | Nura Bio Launches with $73M in Series A | SOUTH SAN FRANCISCO, CA, Nura Bio announced its official launch and a $73 million Series A round led by the Column Group. >> Click here for more funding data on Nura Bio >> To export Nura Bio funding data to PDF and Excel, c... |
| 05.11.2018 | Melbourne’s nura raises $21 million Series A round led by Blackbird Ventures | Becoming Australia’s most successful Kickstarter project in 2016, nura has closed a $21 million Series A round led by existing backer Blackbird Ventures to push the rollout of its flagship product, the nuraphone. According to the startup, t... |
| 13.02.2017 | Nura gets $4.6 million in seed funding for its customizable headphones | We tried out a prototype of Nura’s custom headphones over the summer and liked what we heard. Apparently we weren’t alone in that, as the Australian startup scored a massive $1.8 million on Kickstarter soon after – doubly impressive when yo... |
| - | Nura Bio | “Home | Nura Bio™” |